Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LianBio Gets Chinese Biotech US IPOs Rolling Again But Followers Scant

Health Players Turn Inward-Looking

Executive Summary

Billed as BridgeBio in China, US-based and China-oriented biotech LianBio breaks a long hiatus in US listing for Chinese biotechs.

You may also be interested in...



Chinese Investors Wary Of In-Licensing-Only Biotechs After IPO Setback

The torpedoed IPO application of a Shanghai-based biotech has already triggered a ripple of unease among venture capitalists in China, with some signaling suspension of investment in similar ventures.

Chinese Health Tech Giant Delays US IPO Amid DiDi Fallout

Big data player and “Flatiron of China” is putting off its plans to go public amid regulatory scrutiny over DiDi and other companies listed in the US, but biotech firms need to worry less, says one investor.

China mRNA Player Abogen Gets $300m More As Country Eyes Omicron Threat

From inactivated virus-based to mRNA platforms, the race is on in China to develop vaccines to fight the latest omicron variant, with substantial new funding pouring into one young mRNA company.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145366

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel